4D Molecular Therapeutics Inc. has announced upcoming presentations of clinical trial results at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists, taking place from July 30 to August 2, 2025, in Long Beach, CA. The company will present interim results from the SPECTRA Phase 2a Clinical Trial, which evaluates the intravitreal 4D-150 in adults with diabetic macular edema. The presentation will include a 52-week primary endpoint analysis and a 60-week analysis, with all patients having reached 60 weeks as of the data cutoff date of May 2, 2025. This will be presented by Dr. David Almeida on July 31, 2025. Additionally, results from the PRISM Phase 2b Clinical Trial, assessing the same therapeutic in adults with neovascular age-related macular degeneration, will be presented by Dr. John A. Wells on August 1, 2025. Both presentations will be made available on the 4DMT website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.